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Abstract: Longitudinal studies were carried out to determine trends in CD4 cell counts over a four year period in healthy 
HIV-negative adults in a rural (134 individuals) and an urban (80 individuals) site in Malawi, using TruCount
TM
 and 
FACScount
TM 
platforms. At baseline, median counts and 95% ranges were 890 (359-1954) cells per microlitre (μl) and 
725 (114-1074) cells/μl respectively. 1.5% and 6% respectively had baseline counts below 350 cells/μl and 1.5% and 
2.5% below 250 cells per μl. Transient dips to below 250 cells/μl were observed in seven individuals, with two individuals 
having persistently low CD4 counts over more than one year. Women and individuals from the urban site were 
significantly more likely to have “low CD4 count” (< 500 cells/μl) even when adjusted for other factors. In common with 
neighbouring countries, HIV-negative populations in Malawi have CD4 counts considerably lower than European 
reference ranges, and healthy individuals may have persistently or transiently low counts. Within Malawi, ranges differ 
according to the selected population. 
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INTRODUCTION 
 CD4+ lymphocyte (CD4) counts are routinely used 
world-wide, including many parts of sub-Saharan Africa, to 
determine eligibility for, and monitoring response to, anti-
retroviral therapy (ART) in HIV-positive patients. They are 
used as a measure of the risk of development of 
opportunistic infections. Well-established reference ranges 
from European and North American populations have 
proved inappropriate in some African populations in which 
the range of CD4 counts in apparently healthy HIV-negative 
individuals is significantly lower [1-5], although this finding 
is not replicated in all settings [2, 6, 7]. Less than 350 
cells/μl is considered a threshold for starting ART in HIV-
positive patients without other indications in many high-
income countries [8, 9] although not all [10] and some 
commentators argue that with newer, safer antiretrovirals, 
there should be commencement of therapy at a higher 
threshold of CD4 count [11]. Similar levels of cut-off are 
encouraged for low-income countries where feasible [12] 
despite some evidence that treatment may be delayed further 
without increasing the risk of AIDS related events [13, 14]. 
There is consensus that, in the absence of clinical eligibility, 
it is critical to have a threshold of CD4 count for starting 
ART that ensures a favourable risk-benefit ratio at both 
individual and programme level. In sub-Saharan Africa, the 
WHO recommend starting ART in Stage III disease if the 
CD4 count is <350 cells/μl or if the CD4 count is < 200 
cells/μl irrespective of clinical stage [15]. In Malawi, 
eligibility for ART is usually determined by clinical criteria 
(Stage III or IV disease), but ART is made available to stage 
II or otherwise asymptomatic individuals with CD4 counts 
less than 250cells/μl. 
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 In settings where HIV-negative individuals (and 
therefore presumably relatively immunocompetent HIV-
positive individuals) are frequently found to have CD4 
counts below <350cells/μl (up to 5% of healthy HIV 
negative adults) [2], it is frequently stated that there is 
considerable intra-patient variability and that CD4 count 
may be depressed by acute infections [16, 17]. Some 
published reports on CD4 trends in HIV positive individuals 
describe the variability of CD4 count over time in healthy 
HIV-negative individuals in sub-Saharan Africa but data are 
not presented on whether the extremes that overlap with 
eligibility for ART are transient or persistent effects [18, 19]. 
It is likely that whatever variability is observed, that CD4 
counts will vary more in HIV-positive individuals even if 
clinically stable [20, 21], however, an understanding of the 
“normal” variability in uninfected individuals is key to 
interpretation of clinical thresholds, reference ranges and 
mathematical models predicting risk of opportunistic 
diseases and impact of HIV [2]. 
 As part of two immunological studies in Malawi, one of 
contacts of tuberculosis cases and one of safety and 
immunogenicity of pneumococcal vaccines we performed 
sequential CD4 counts on persistently HIV-negative adults 
over a four year period. 
MATERIALS AND METHODS 
 HIV-negative spouses of smear positive tuberculosis 
patients consented to recruitment for a follow–up study of M. 
tuberculosis infection and disease rates, in Karonga, a rural 
district of Malawi. At baseline, 6, 12, 24 and 36 months, 
individuals were counselled and tested for HIV testing and 
had CD4 counts performed using flow cytometry. Initial 
HIV-antibody testing of plasma was performed using an 
ELISA (Organon Vironostika) and particle agglutination test 
(Edgware modification of the Serodia). Samples giving 
discrepant results were repeated in duplicate using the same 
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two tests. EDTA-anticoagulated whole blood was labelled 
with the TriTEST
TM
 CD3 FITC/CD4 PE/CD45 PerCP 
monoclonal antibody mix in TruCount
TM
 tubes to determine 
absolute cell counts. Samples were acquired on a 
FACSCalibur
TM
 and analysed using MultiSET
TM
 software. 
All reagents, hardware and software were purchased from 
Becton Dickinson (UK) and used according to 
manufacturer’s instructions. 
 Healthy HIV-negative individuals consented to 
recruitment as controls in a study of immune response to 
pneumococcal conjugate vaccine in Blantyre, a large city in 
Malawi. Participants came forward as volunteers following a 
public advert. CD4 counts were measured at baseline and 
one month following each of two doses of conjugate 
pneumococcal vaccine then subsequently every six to a 
maximum of 48 months. The HIV status of participants was 
measured using a twin EIA method (Vironostika HIV uni-
Form II plus O, Biomerieux, Boxtel, Netherlands and Murex 
HIV-1.2.0, Dartford, UK). Discrepant results were checked 
using two rapid tests (Determine HIV-1/2/O, Abbott 
Laboratories, Abbott and Uni-Gold Recombinant HIV-1/2 
Trinity Biotech,). CD4 counts were measured using a 
FACScount
TM
 (Becton Dickinson) system according to the 
manufacturer’s instructions. The Laboratory participated in 
the UK’s national external quality assurance programme for 
CD4 count measurement; during the study period 25 CD4 
count measurements were returned. On no occasion was a 
result returned that was below the trimmed mean, with 21 of 
the 25 within +1 SD of trimmed mean. HIV-status was 
assessed throughout the period of follow-up by sequential 
testing. Individuals who HIV-seroconverted during either 
study were excluded from this analysis at the last time-point 
at which they were HIV-antibody negative. 
 Ranges of CD4 count, with 95% ranges, means and 
standard deviations are given, and the chi squared test used 
to compare grouped indices by site. 
 The rural study was approved by the National Health 
Science Research Committee of Malawi and the London 
School of Hygiene ethical review board. The urban study 
was approved by the Malawi College of Medicine Research 
Ethics Committee and the Liverpool School of Tropical 
Medicine, institutional review board. 
RESULTS 
 In Karonga 134 individuals were recruited and had CD4 
counts performed. In 72 individuals CD4 counts were 
available at two time points, in 52 at three time points and in 
20 at four time points. In the urban Blantyre population, 80 
individuals were recruited; 75 had sampling at two time 
points, 59 at three and 53 at four or more, to a maximum of 
16. Approximately half of the participants had received the 
study vaccine. 
 The Karonga population was older (mean age 42 years, 
compared to 33 years) and a higher proportion were females 
(63% to 29%) than in Blantyre. 
 The distribution of total lymphocyte count was similar 
between the two sites when all samples with accompanying 
haematological indices were considered (Blantyre range 0.36 
to 5.0, mean 1.91, standard deviation 0.734, with two 
excluded outliers over 20, n=432, Karonga range 0.47 to 
4.68, mean 2.08, sd 0.733, n=258). 
 Samples in Karonga were processed a mean of 3.4 hours 
after collection (range 0 to 8 hours). Samples in Blantyre 
were processed on the day of collection i.e. within six hours 
maximum, but times for individual samples were not 
recorded. 
 The ranges of CD4 counts differed between the sites, 
both at baseline and when all results from repeated 
samplings were considered together. Summary statistics on 
individuals at the urban site were lower than at the rural site 
in both males and females (Table 1). The crude risk of “low 
CD4 count” using an international range (<500cells/μl) was 
significantly higher in Blantyre than Karonga (24% 
compared to 9%, chi=8.85, p=0.003) and remained 
significantly different when adjusted for age and sex (20% vs 
7%, chi=7.38, p=0.006). Data on 59 HIV-negative 
individuals from a previous community cross-sectional 
survey in Karonga are also presented [22]. Low CD4 count 
was associated with lymphopenia at both sites. 
 The distribution of all CD4 counts by site is displayed in 
Fig. (1). 
Table 1. Range and Distribution of CD4 Cell Counts in Karonga and Blantyre 
 
Baseline  
n Range 95% Range Mean (sd) Median <350 Cells/μl <250 Cells/μl 
Karonga (rural) 134 208-2335 359-1954 949 (364) 890 1.5% 1.5% 
   Male 49 356-1753 376-1680 921 (289) 876   
  Female 85 208-2335 255-2206 964 (402) 938   
Blantyre (urban) 80 114-1736 114-1074 720 (281) 725 6% 2.5% 
  Male 57 114-1736 114-1144 702 (287) 669   
  Female 23 307-1315 307-1315 763 (269) 809   
All 214 114-2335 276-1730 863 (353) 836 3% 2% 
Karonga Survey 59 130-1654 199-1585 922 (348) 892 5% 1.5% 
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 For the purposes of examining trends in CD4, combined 
urban/rural baseline results were grouped into “bands” of 0-
250 (Very low), 251-350 (Low), 351-500 (Lower normal) 
and >500 cells/μl (Higher normal). Of those with follow-up, 
108/151 (72%) of individuals remained in the same band for 
the duration of followup, 1/3 Very low, 0/3 Low, 3/22 Low 
normal, 104/123 Normal. 
 24/151 moved to a higher band (some transiently) and 
24/151 to a lower band (some transiently). A transient dip to 
239 cells/μl in one individual who otherwise consistently had 
CD4 counts > 500 cells/μl was known to coincide with a 
non-malarial, non-bacteraemic acute febrile illness. The 
detail for each banding is given in Table 2. 
 To give a more detailed picture of the stability of CD4 
count in a sample of the group, trends over four years for 
women aged 20-29 with at least one year of follow-up are 
presented graphically in Fig. (2). These graphs include two 
individuals, highlighted in Fig. (2), from the rural 
population, who had profoundly low CD4 counts (<250 
cells/μl) but were clinically well throughout the study and 
were persistently HIV-negative. On 2-year follow-up after 
the conclusion of the study, one had died suddenly with 
haematemesis (suggesting occult abdominal disease, despite 
regular clinical follow-up) and the other remains clinically 
well, although all haematological indices remain slightly 
low, suggesting the low CD4 count was part of a general 
picture rather than a specific deficit. The figure also includes 
two individuals (also highlighted) with transient “dips” to 
below 250 cells/μl. 
DISCUSSION 
 The ranges of CD4 counts seen in these studies are 
similar to those from studies in Ethiopia, Central African 
Republic, Guinea Bissau and Botswana (Table 3) and are 
significantly lower than the those found in European 
populations [1]. In common with the other populations with 
lower mean counts, 3% of this Malawian population had a 
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Fig. (1). Distribution of all CD4 counts by site of study. 
Table 2. Change in CD4 Cell Count Band Over Course of Study 
 
Initial CD4 Count (Cells/l) Moved to Lower Band Same Band Throughout Moved to Higher Band  
Very low <=250 n/a 1 3 3 
Low 250-350 0 0 3 3 
Lower normal 350-500 5 3 18 22 
Higher normal 500+ 19 104 n/a 123 
Total 24 108 24 151 
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CD4 count less than 350 cells/μl on a single sampling, and 
9% had a low CD4 count at some point when sampled 
repeatedly over a 3 year period. In this study, each time the 
individuals were sampled, the HIV test was repeated so the 
low CD4 counts are known not to be related to false-negative 
HIV tests, as might occur in single-sampling studies. 
 In nine individuals a CD4 count was recorded below a 
threshold determining eligibility for ART in HIV-positive 
patients according to Malawi ART programme guidelines 
(250 cells/μl). In seven of these people (all from Blantyre), 
the low CD4 count was an isolated event restored to a 
“normal” level one month later. In two (both from Karonga), 
this was part of a persistently low CD4 count over more than 
one year. All the transient dips were found in the urban site, 
and although one was known to coincide with an acute 
febrile illness, assay-related effects cannot be discounted. 
The differences may, however, be a function of the increased 
frequency of sampling in the urban population, poorer health 
or other psychological or biological urban factors. Several of 
these individuals are represented in Fig. (2). 
 Extremely low CD4 counts are observed in some 
apparently healthy HIV-negative subjects in Africa. When 
this is persistent, as with two individuals in the rural study, it 
is likely to represent occult disease of some severity or a 
chronic haemapoetic disorder. In others this may represent 
the end of a normal distribution, however low counts in 
apparently healthy individuals are worthy of investigation. 
 We observed clear and significant differences between 
the sites. This may be inherent to the population, due to the 
selection processes for the different studies or an artefact of 
the different laboratory methods for estimation of CD4 
count. It is notable that total lymphocyte counts had similar 
distributions in the two sites. Several North American 
studies have demonstrated consistent inter-laboratory 
variability in measurements despite shared protocols and 
participation in quality assurance programmes [23-25]. Due 
to the distance between laboratories we were unable to 
conduct comparability experiments on shared samples 
although comparison studies at one of the sites found no 
systematic variation in results between the two platforms 
even at low CD4 counts [26] as has been demonstrated in 
similar settings [27] and UK’s national external quality 
assurance programme shows no difference in mean CD4 
count returns. It is possible that the recent exposure of the 
rural group to tuberculosis might have had an effect on CD4 
count as it is known that active disease may depress the level 
[28]. However none of the individuals in this group 
progressed to clinical tuberculosis and the range was actually 
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Fig. (2). Details of trends of CD4 count over 4 years in a sample of 20 women aged 20-39 years by individual. Line at 250cells/l. 
Footnote: Two individuals with persistently low CD4 counts are highlighted _____ and two with transient dips - - - - - - - . 
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slightly higher than that seen in the urban group. There was 
no suggestion from the data that the administration of the 
conjugate pneumococcal vaccine was suppressing the CD4 
count as baseline counts would have been unaffected. 
Although the differences between our two sites were not so 
great that different conclusions to the study would be drawn, 
the differences highlight that sampling a single population 
within a country may not give an accurate reference range 
for country-wide application, and that any reference range 
may be dependent on the platform used for CD4 counting. 
 The higher values seen in the women in our studies are 
consistent with findings elsewhere [29, 30], and as found in 
another study [30] we also observed a decrease with age (not 
presented) although this was not significant. 
 Diurnal variation in CD4 count is known to occur in both 
HIV-negative and HIV-positive individuals, with counts 
increasing during the day particularly in those who are HIV-
negative [31]. In both studies, where time of venepuncture 
was recorded, 97% of samples were collected between a four 
hour morning period, so timing is unlikely to account for any 
intra-patient variability. 
 Overall CD4 count may be a less useful marker of 
prognosis in AIDS care in sub-Saharan Africa than 
elsewhere [32], but given the investment in CD4 
infrastructure, it is important to ensure that its usefulness is 
optimised locally. Current Malawi ART programme 
guidelines define eligibility for ART on clinical grounds 
(WHO stage III or IV disease) or with a CD4 count <250 
cells/μl, and CD4 counts are becoming more widely 
available. The studies presented here provide population data 
against which CD4 counts in HIV-positive individuals may 
be evaluated and provide insight into the natural variation in 
CD4 counts both between and within individuals in this 
setting. 
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